JP2024522769A - 自己免疫性血液学的疾患を治療する方法 - Google Patents

自己免疫性血液学的疾患を治療する方法 Download PDF

Info

Publication number
JP2024522769A
JP2024522769A JP2023577713A JP2023577713A JP2024522769A JP 2024522769 A JP2024522769 A JP 2024522769A JP 2023577713 A JP2023577713 A JP 2023577713A JP 2023577713 A JP2023577713 A JP 2023577713A JP 2024522769 A JP2024522769 A JP 2024522769A
Authority
JP
Japan
Prior art keywords
iptacopan
subject
patient
weeks
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522769A5 (cg-RX-API-DMAC10.html
Inventor
ウェレンシーク，アンナ スベーニャ シューバルト
ユンゲ，グイド
ホルブロ，トーマス
チャウラ，ラーガバ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024522769A publication Critical patent/JP2024522769A/ja
Publication of JP2024522769A5 publication Critical patent/JP2024522769A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023577713A 2021-06-18 2022-06-17 自己免疫性血液学的疾患を治療する方法 Pending JP2024522769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212465P 2021-06-18 2021-06-18
US63/212,465 2021-06-18
PCT/IB2022/055639 WO2022264101A1 (en) 2021-06-18 2022-06-17 Method of treating an autoimmune hematological disorder

Publications (2)

Publication Number Publication Date
JP2024522769A true JP2024522769A (ja) 2024-06-21
JP2024522769A5 JP2024522769A5 (cg-RX-API-DMAC10.html) 2025-06-04

Family

ID=82595001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577713A Pending JP2024522769A (ja) 2021-06-18 2022-06-17 自己免疫性血液学的疾患を治療する方法

Country Status (5)

Country Link
US (1) US20240277689A1 (cg-RX-API-DMAC10.html)
EP (1) EP4355329A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024522769A (cg-RX-API-DMAC10.html)
CN (1) CN117500500A (cg-RX-API-DMAC10.html)
WO (1) WO2022264101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240109861A1 (en) * 2020-12-30 2024-04-04 Medshine Discovery Inc. Series of piperidine-substituted benzoic acid compounds, and use thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
AU2024417894A1 (en) * 2024-01-10 2026-07-30 Hebei Yiling Medicine Research Institute Co. Ltd. Piperidinyl indole derivative, preparation method therefor and use thereof
WO2026093943A1 (en) 2024-10-31 2026-05-07 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526576A (ja) * 2013-07-15 2016-09-05 ノバルティス アーゲー ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120168469A (zh) 2020-05-18 2025-06-20 诺华股份有限公司 Lnp023的结晶形式

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526576A (ja) * 2013-07-15 2016-09-05 ノバルティス アーゲー ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERENTSEN, SIGBJORN ET AL.: "Novel insights into the treatment of complement-mediated hemolytic anemias", THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 10, JPN6026021941, January 2019 (2019-01-01), pages 1 - 20, ISSN: 0005875196 *
JANG, JUN HO ET AL.: "Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label pr", BLOOD ADVANCES, vol. 6, no. 15, JPN6026021944, 2 August 2022 (2022-08-02), pages 4450 - 4460, ISSN: 0005875199 *
JANG, JUN-HO ET AL.: "12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemo", BLOOD, vol. 138, no. 1, JPN6026021943, 5 November 2021 (2021-11-05), pages 2173, ISSN: 0005875198 *
RISITANO, ANTONIO M. ET AL.: "Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturn", THE LANCET HAEMATOLOGY, vol. 8, no. 5, JPN6026021942, May 2021 (2021-05-01), pages 344 - 354, ISSN: 0005875197 *

Also Published As

Publication number Publication date
EP4355329A1 (en) 2024-04-24
CN117500500A (zh) 2024-02-02
WO2022264101A1 (en) 2022-12-22
US20240277689A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
US20240025975A1 (en) Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
JP2025146943A (ja) 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
EP4355329A1 (en) Method of treating an autoimmune hematological disorder
JP7823117B2 (ja) 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与
JP7328151B2 (ja) Ｈｅｒ２陽性がんの処置
TW201718014A (zh) C5抑制劑於移植相關微血管病之用途
JP2019530728A (ja) 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
JP2024517234A (ja) 非典型溶血性尿毒症症候群の処置のためのイプタコパン
JP7713489B2 (ja) Ｂ因子阻害剤の使用方法
KR20260042485A (ko) 궤양성 대장염의 치료를 위한 오베파지모드
TW202533829A (zh) 用於治療anca相關性血管炎的因子b抑制劑
WO2022036151A1 (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
JP2024505194A (ja) 寛容を誘導する方法及び組成物
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
TW202508580A (zh) 使用因子b抑制劑之方法
TW202539668A (zh) 使用索樂匹尼布處置免疫性血小板減少症的方法
US20260132215A1 (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
TW202535375A (zh) 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
WO2025054498A1 (en) Methods of treating hidradenitis suppurativa
JP2022510258A (ja) デビミスタットを使用して急性骨髄性白血病を治療するための治療方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602